Evaluating the Relationship Between Serum Level of Interleukin-6 and Rheumatoid Arthritis Severity and Disease Activity.


Journal

Current rheumatology reviews
ISSN: 1875-6360
Titre abrégé: Curr Rheumatol Rev
Pays: United Arab Emirates
ID NLM: 101261938

Informations de publication

Date de publication:
2020
Historique:
received: 12 10 2018
revised: 27 12 2018
accepted: 29 01 2019
pubmed: 8 2 2019
medline: 5 8 2021
entrez: 8 2 2019
Statut: ppublish

Résumé

The aim of this study was to evaluate the relationship between Interleukin-6 (IL-6) serum level and the severity and activity of Rheumatoid Arthritis (RA). In this cross-sectional study, 120 RA patients referred to the rheumatology clinic, the patients were diagnosed by rheumatologists according to ACR / EULAR 2010 criteria. Based on DAS28 score the patients were divided into 4 groups: Remission, Mild, Moderate and Severe. Each group contained 30 patients. Serum levels of Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP), anti-Cyclic Citrullinated Peptide (anti-CCP) and Rheumatoid Factor (RF) and serum levels of IL-6, were measured. The relationship between these factors was measured and compared to the relationship between IL-6 and these factors, and the activity of the disease was evaluated based on DAS-28. This study showed that the serum level of IL-6 has a significant relationship with RA activity according to DAS-28 (P value <0.001). There is also a significant relationship between the ESR level, the number of painful joints, and the number of swollen joints, and the severity of the disease based on VAS. Generally the findings of this study indicate that serum level of IL-6 plays an important role in the severity and activity of RA disease and can be considered as a determining factor in evaluating the severity of RA in RA patients and it is a good guide for a step up or down of treatment.

Identifiants

pubmed: 30727900
pii: CRR-EPUB-96405
doi: 10.2174/1573397115666190206144223
doi:

Substances chimiques

Anti-Citrullinated Protein Antibodies 0
IL6 protein, human 0
Interleukin-6 0
C-Reactive Protein 9007-41-4
Rheumatoid Factor 9009-79-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

249-255

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Elham Rajaei (E)

Golestan Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Karim Mowla (K)

Golestan Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Qodratollah Hayati (Q)

Golestan Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Ali Ghorbani (A)

Department of Nephrology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Mehrdad Dargahi-Malamir (M)

Golestan Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Saeed Hesam (S)

Department of Statistics and Epidemiology School of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Zeinab Deris Zayeri (ZD)

Golestan Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH